Household & Personal Products
Compare Stocks
4 / 10Stock Comparison
SLSN vs COTY vs EL vs SKIN
Revenue, margins, valuation, and 5-year total return — side by side.
Household & Personal Products
Household & Personal Products
Household & Personal Products
SLSN vs COTY vs EL vs SKIN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Household & Personal Products | Household & Personal Products | Household & Personal Products | Household & Personal Products |
| Market Cap | $92M | $2.20B | $30.80B | $118M |
| Revenue (TTM) | $62M | $5.79B | $14.84B | $296M |
| Net Income (TTM) | $1M | $-536M | $-248M | $-6M |
| Gross Margin | 24.8% | 61.9% | 74.7% | 64.9% |
| Operating Margin | 1.9% | -0.3% | 6.8% | -3.6% |
| Forward P/E | 18.6x | 9.2x | 38.4x | — |
| Total Debt | $15M | $4.25B | $9.44B | $379M |
| Cash & Equiv. | $1M | $257M | $2.92B | $233M |
SLSN vs COTY vs EL vs SKIN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Nov 20 | May 26 | Return |
|---|---|---|---|
| Solesence, Inc. Com… (SLSN) | 100 | 175.7 | +75.7% |
| Coty Inc. (COTY) | 100 | 34.8 | -65.2% |
| The Estée Lauder Co… (EL) | 100 | 34.8 | -65.2% |
| The Beauty Health C… (SKIN) | 100 | 9.0 | -91.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SLSN vs COTY vs EL vs SKIN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
SLSN carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 40.4%, EPS growth 179.0%, 3Y rev CAGR 21.1%
- 160.0% 10Y total return vs EL's 10.8%
- 40.4% revenue growth vs SKIN's -10.0%
- 1.7% margin vs COTY's -9.3%
COTY is the #2 pick in this set and the best alternative if income & stability and sleep-well-at-night is your priority.
- Dividend streak 1 yrs, beta 1.08, yield 0.6%
- Lower volatility, beta 1.08, current ratio 0.77x
- Lower P/E (9.2x vs 38.4x)
- Beta 1.08 vs SLSN's 2.02
EL is the clearest fit if your priority is defensive.
- Beta 1.73, yield 2.0%, current ratio 1.30x
- 2.0% yield, vs COTY's 0.6%, (2 stocks pay no dividend)
- +46.3% vs SLSN's -57.2%
SKIN lags the leaders in this set but could rank higher in a more targeted comparison.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 40.4% revenue growth vs SKIN's -10.0% | |
| Value | Lower P/E (9.2x vs 38.4x) | |
| Quality / Margins | 1.7% margin vs COTY's -9.3% | |
| Stability / Safety | Beta 1.08 vs SLSN's 2.02 | |
| Dividends | 2.0% yield, vs COTY's 0.6%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +46.3% vs SLSN's -57.2% | |
| Efficiency (ROA) | 2.0% ROA vs COTY's -4.7%, ROIC 15.3% vs 2.3% |
SLSN vs COTY vs EL vs SKIN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
SLSN vs COTY vs EL vs SKIN — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
SLSN leads in 2 of 6 categories
EL leads 1 • COTY leads 1 • SKIN leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
EL leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
EL is the larger business by revenue, generating $14.8B annually — 238.8x SLSN's $62M. SLSN is the more profitable business, keeping 1.7% of every revenue dollar as net income compared to COTY's -9.3%. On growth, EL holds the edge at +4.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $62M | $5.8B | $14.8B | $296M |
| EBITDAEarnings before interest/tax | $2M | $314M | $1.6B | $9M |
| Net IncomeAfter-tax profit | $1M | -$536M | -$248M | -$6M |
| Free Cash FlowCash after capex | -$11M | $311M | $1.3B | $29M |
| Gross MarginGross profit ÷ Revenue | +24.8% | +61.9% | +74.7% | +64.9% |
| Operating MarginEBIT ÷ Revenue | +1.9% | -0.3% | +6.8% | -3.6% |
| Net MarginNet income ÷ Revenue | +1.7% | -9.3% | -1.7% | -2.0% |
| FCF MarginFCF ÷ Revenue | -18.0% | +5.4% | +8.7% | +9.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | -13.5% | -1.3% | +4.6% | -6.7% |
| EPS Growth (YoY)Latest quarter vs prior year | -150.0% | 0.0% | -45.5% | +38.0% |
Valuation Metrics
COTY leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, COTY's 9.4x EV/EBITDA is more attractive than SKIN's 7331.2x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $92M | $2.2B | $30.8B | $118M |
| Enterprise ValueMkt cap + debt − cash | $106M | $6.2B | $37.3B | $264M |
| Trailing P/EPrice ÷ TTM EPS | 18.57x | -5.68x | -27.08x | -5.69x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 9.16x | 38.44x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 17.42x | 9.36x | 20.88x | 7331.15x |
| Price / SalesMarket cap ÷ Revenue | 1.75x | 0.37x | 2.16x | 0.39x |
| Price / BookPrice ÷ Book value/share | 5.66x | 0.55x | 7.95x | 2.02x |
| Price / FCFMarket cap ÷ FCF | — | 7.93x | 45.97x | 3.17x |
Profitability & Efficiency
SLSN leads this category, winning 8 of 9 comparable metrics.
Profitability & Efficiency
SLSN delivers a 6.2% return on equity — every $100 of shareholder capital generates $6 in annual profit, vs $-14 for COTY. SLSN carries lower financial leverage with a 1.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to SKIN's 6.20x. On the Piotroski fundamental quality scale (0–9), SKIN scores 7/9 vs EL's 4/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | +6.2% | -14.1% | -6.3% | -9.4% |
| ROA (TTM)Return on assets | +2.0% | -4.7% | -1.3% | -1.2% |
| ROICReturn on invested capital | +15.3% | +2.3% | +6.5% | -6.8% |
| ROCEReturn on capital employed | +24.7% | +2.6% | +6.3% | -4.5% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 5 | 4 | 7 |
| Debt / EquityFinancial leverage | 1.02x | 1.07x | 2.44x | 6.20x |
| Net DebtTotal debt minus cash | $14M | $4.0B | $6.5B | $146M |
| Cash & Equiv.Liquid assets | $1M | $257M | $2.9B | $233M |
| Total DebtShort + long-term debt | $15M | $4.2B | $9.4B | $379M |
| Interest CoverageEBIT ÷ Interest expense | 3.37x | 0.23x | 1.14x | 0.81x |
Total Returns (Dividends Reinvested)
SLSN leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SLSN five years ago would be worth $9,701 today (with dividends reinvested), compared to $707 for SKIN. Over the past 12 months, EL leads with a +46.3% total return vs SLSN's -57.2%. The 3-year compound annual growth rate (CAGR) favors SLSN at 22.9% vs SKIN's -56.4% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -13.3% | -19.6% | -19.8% | -35.0% |
| 1-Year ReturnPast 12 months | -57.2% | -45.3% | +46.3% | -35.9% |
| 3-Year ReturnCumulative with dividends | +85.7% | -79.4% | -55.6% | -91.7% |
| 5-Year ReturnCumulative with dividends | -3.0% | -75.8% | -68.3% | -92.9% |
| 10-Year ReturnCumulative with dividends | +160.0% | -83.0% | +10.8% | -91.6% |
| CAGR (3Y)Annualised 3-year return | +22.9% | -40.9% | -23.7% | -56.4% |
Risk & Volatility
Evenly matched — COTY and EL each lead in 1 of 2 comparable metrics.
Risk & Volatility
COTY is the less volatile stock with a 1.08 beta — it tends to amplify market swings less than SLSN's 2.02 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. EL currently trades 70.1% from its 52-week high vs SLSN's 23.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.02x | 1.08x | 1.73x | 2.00x |
| 52-Week HighHighest price in past year | $5.63 | $5.34 | $121.64 | $2.69 |
| 52-Week LowLowest price in past year | $0.78 | $1.96 | $57.91 | $0.76 |
| % of 52W HighCurrent price vs 52-week peak | +23.1% | +46.8% | +70.1% | +33.8% |
| RSI (14)Momentum oscillator 0–100 | 52.7 | 70.6 | 66.6 | 52.1 |
| Avg Volume (50D)Average daily shares traded | 37K | 7.9M | 4.6M | 760K |
Analyst Outlook
Evenly matched — COTY and EL each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: COTY as "Hold", EL as "Hold", SKIN as "Hold". Consensus price targets imply 60.4% upside for COTY (target: $4) vs 25.1% for EL (target: $107). For income investors, EL offers the higher dividend yield at 2.01% vs COTY's 0.61%.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold | Hold | Hold |
| Price TargetConsensus 12-month target | — | $4.01 | $106.73 | $1.30 |
| # AnalystsCovering analysts | — | 33 | 46 | 13 |
| Dividend YieldAnnual dividend ÷ price | — | +0.6% | +2.0% | — |
| Dividend StreakConsecutive years of raises | — | 1 | 0 | — |
| Dividend / ShareAnnual DPS | — | $0.02 | $1.72 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +0.1% | 0.0% |
SLSN leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). EL leads in 1 (Income & Cash Flow). 2 tied.
SLSN vs COTY vs EL vs SKIN: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is SLSN or COTY or EL or SKIN a better buy right now?
For growth investors, Solesence, Inc.
Common Stock (SLSN) is the stronger pick with 40. 4% revenue growth year-over-year, versus -10. 0% for The Beauty Health Company (SKIN). Solesence, Inc. Common Stock (SLSN) offers the better valuation at 18. 6x trailing P/E, making it the more compelling value choice. Analysts rate Coty Inc. (COTY) a "Hold" — based on 33 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — SLSN or COTY or EL or SKIN?
On forward P/E, Coty Inc.
is actually cheaper at 9. 2x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — SLSN or COTY or EL or SKIN?
Over the past 5 years, Solesence, Inc.
Common Stock (SLSN) delivered a total return of -3. 0%, compared to -92. 9% for The Beauty Health Company (SKIN). Over 10 years, the gap is even starker: SLSN returned +160. 0% versus SKIN's -91. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — SLSN or COTY or EL or SKIN?
By beta (market sensitivity over 5 years), Coty Inc.
(COTY) is the lower-risk stock at 1. 08β versus Solesence, Inc. Common Stock's 2. 02β — meaning SLSN is approximately 87% more volatile than COTY relative to the S&P 500. On balance sheet safety, Solesence, Inc. Common Stock (SLSN) carries a lower debt/equity ratio of 102% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.
05Which is growing faster — SLSN or COTY or EL or SKIN?
By revenue growth (latest reported year), Solesence, Inc.
Common Stock (SLSN) is pulling ahead at 40. 4% versus -10. 0% for The Beauty Health Company (SKIN). On earnings-per-share growth, the picture is similar: Solesence, Inc. Common Stock grew EPS 179. 0% year-over-year, compared to -609. 8% for Coty Inc.. Over a 3-year CAGR, SLSN leads at 21. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — SLSN or COTY or EL or SKIN?
Solesence, Inc.
Common Stock (SLSN) is the more profitable company, earning 8. 1% net margin versus -7. 9% for The Estée Lauder Companies Inc. — meaning it keeps 8. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SLSN leads at 9. 8% versus -6. 9% for SKIN. At the gross margin level — before operating expenses — EL leads at 73. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is SLSN or COTY or EL or SKIN more undervalued right now?
On forward earnings alone, Coty Inc.
(COTY) trades at 9. 2x forward P/E versus 38. 4x for The Estée Lauder Companies Inc. — 29. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for COTY: 60. 4% to $4. 01.
08Which pays a better dividend — SLSN or COTY or EL or SKIN?
In this comparison, EL (2.
0% yield), COTY (0. 6% yield) pay a dividend. SLSN, SKIN do not pay a meaningful dividend and should not be held primarily for income.
09Is SLSN or COTY or EL or SKIN better for a retirement portfolio?
For long-horizon retirement investors, Coty Inc.
(COTY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 08), 0. 6% yield). The Beauty Health Company (SKIN) carries a higher beta of 2. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (COTY: -83. 0%, SKIN: -91. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between SLSN and COTY and EL and SKIN?
Both stocks operate in the Consumer Defensive sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: SLSN is a small-cap high-growth stock; COTY is a small-cap quality compounder stock; EL is a mid-cap quality compounder stock; SKIN is a small-cap quality compounder stock. COTY, EL pay a dividend while SLSN, SKIN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.